Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,690
  • Shares Outstanding, K 68,365
  • Annual Sales, $ 590 K
  • Annual Income, $ -45,850 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.42
  • Price/Sales 207.52
  • Price/Cash Flow N/A
  • Price/Book 2.67

Options Overview Details

View History
  • Implied Volatility 150.85% (+12.86%)
  • Historical Volatility 55.58%
  • IV Percentile 44%
  • IV Rank 20.32%
  • IV High 483.26% on 02/09/26
  • IV Low 66.07% on 08/13/25
  • Expected Move (DTE 23) 0.4675 (28.33%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 777
  • Volume Avg (30-Day) 312
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 27,556
  • Open Int (30-Day) 27,992
  • Expected Range 1.1825 to 2.1175

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 5
  • High Estimate $-0.11
  • Low Estimate $-0.16
  • Prior Year $-0.20
  • Growth Rate Est. (year over year) +35.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5400 +7.14%
on 04/08/26
1.8700 -11.76%
on 03/23/26
-0.1500 (-8.33%)
since 03/20/26
3-Month
1.4800 +11.49%
on 02/05/26
3.0500 -45.90%
on 01/23/26
-1.2400 (-42.91%)
since 01/21/26
52-Week
1.4800 +11.49%
on 02/05/26
4.5550 -63.78%
on 07/18/25
-1.1700 (-41.49%)
since 04/21/25

Most Recent Stories

More News
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced...

CRDF : 1.6500 (-7.30%)
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

SAN DIEGO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range...

CRDF : 1.6500 (-7.30%)
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Operating...

CRDF : 1.6500 (-7.30%)
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6500 (-7.30%)
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6500 (-7.30%)
Cardiff Oncology to Participate in Three Upcoming Investor Conferences 

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6500 (-7.30%)
Cardiff Oncology: Q4 Earnings Snapshot

Cardiff Oncology: Q4 Earnings Snapshot

CRDF : 1.6500 (-7.30%)
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of...

CRDF : 1.6500 (-7.30%)
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.6500 (-7.30%)
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

-  Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients...

CRDF : 1.6500 (-7.30%)

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 1.8998
2nd Resistance Point 1.8499
1st Resistance Point 1.7499
Last Price 1.6500
1st Support Level 1.6000
2nd Support Level 1.5501
3rd Support Level 1.4501

See More

52-Week High 4.5550
Fibonacci 61.8% 3.3803
Fibonacci 50% 3.0175
Fibonacci 38.2% 2.6546
Last Price 1.6500
52-Week Low 1.4800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.